Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 3 1Phase 1 1

Status

Terminated 3

Sponsor Class

OTHER 7INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Gynecologic 1

Conditions

Glioma 1Glioblastoma 1Endometrial Cancer Recurrent 1

Interventions

Carboplatin 272Paclitaxel 267Gemcitabine 244Bevacizumab 225Cisplatin 216pembrolizumab 213Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 99Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 80Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Ipilimumab 64Bortezomib 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × TIC10 compound × Clear all
NCT03295396 2025-07-28

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

Jazz Pharmaceuticals

Phase 2 Terminated
73 enrolled 13 charts 1 FDA
CNS

Glioma

NCT02525692 2024-12-24

Oral ONC201 in Adult Recurrent Glioblastoma

Jazz Pharmaceuticals

Phase 2 Terminated
84 enrolled 14 charts 1 FDA
CNS

Glioblastoma

NCT03485729 2024-12-24

ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer

Jazz Pharmaceuticals

Phase 2 Terminated
27 enrolled 11 charts
Gynecologic

Endometrial Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡